Q-omics provides the consensus-scored ZNF100 profile across patient tissues and cancer cell-line models. ZNF100 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF100 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, ZNF100 RNA expression shows 21,033 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, BLCA, and UVM as cancer lineages where ZNF100 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF100 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF100 survival associations across molecular data types. ZNF100 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF100 RNA expression–survival associations across cancer types. High ZNF100 expression shows unfavorable associations in UVM, but favorable associations in LUAD, HNSC, BLCA, BRCA and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF100 RNA expression.
This table summarizes ZNF100 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF100. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF100 shows higher tumor expression in BLCA, UCEC, STAD, BRCA, CHOL and LIHC. The BLCA box plot shows higher ZNF100 RNA expression in tumor versus normal tissue (log2 FC = +0.962, t-test p = .001).
This table shows molecular features associated with ZNF100 in patient tissues and cancer cell lines. In patient samples, ZNF100 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF100 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
